IMAGE: A DNA-based nanogel (shown above) is broken down in cancer cells to release chemotherapy drugs.
view more
Credit: Adapted from Nano Letters 2020, DOI: 10.1021/acs.nanolet.0c03671
Current chemotherapy regimens slow cancer progression and save lives, but these powerful drugs affect both healthy and cancerous cells. Now, researchers reporting in ACS’ Nano Letters have designed DNA-based nanogels that only break down and release their chemotherapeutic contents within cancer cells, minimizing the impacts on normal ones and potentially eliminating painful and uncomfortable side effects.
Once ingested or injected, chemotherapy medications move throughout the body, indiscriminately affecting healthy cells along with those that are responsible for disease. Since many of these drugs are toxic to all cells, the desired tumor shrinkage can be accompanied by undesirable side effects, such as hair loss, gastrointestinal issues and fatigue. Nanogels made of DNA are one way that these drugs could be delivered, but they would still enter all cells. Tianhu Li, Teck-Peng Loh and colleagues reasoned that biomarkers — proteins or other components that are present in differing amounts in cancer cells and their healthy counterparts — could play a role in breaking down a nanogel, causing it to release its contents only in those that are cancerous. A biomarker called FEN1, a repair enzyme that cuts certain types of DNA, is present in larger amounts in cancer cells compared with healthy ones. The researchers wanted to see whether they could design a DNA nanogel that would specifically be degraded in cancer cells by FEN1.
To make DNA nanogels, the researchers used special DNA structures that FEN1 could recognize and cut. With cell-free systems, the researchers observed that the DNA-based nanogels were broken down by FEN1 but not by other DNA repair enzymes or compounds. When live cells were incubated with the DNA-based nanogels, healthy ones did not have enough FEN1 to break them down, but cancer cells did. When the chemotherapeutic drugs doxorubicin and vinorelbine were incorporated into the nanogel, human breast cancer cells died at higher rates than normal, healthy breast cells. These findings indicate DNA-based nanogels can introduce drugs into cancer cells with a high specificity, reducing the risk of side effects. The researchers say that the nanogels also could be used as probes for the biomarker enzyme, helping physicians more directly diagnose cancer compared with current methods.
The authors acknowledge funding from Northwestern Polytechnical University in China and the Agency for Science, Technology and Research in Singapore.
The abstract that accompanies this paper is available here.
The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.
To automatically receive news releases from the American Chemical Society, contact newsroom@acs.org.
###
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.